Trial intelligence / Profile preview

Alectinib or Crizotinib Roll-over Study in ALK/RET-positive Cancers (China)

CTR20222640Phase 3Terminated

Sponsor

Roche

Start

Oct 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1